In a landmark development for cardiovascular medicine, Cyclarity Therapeutics has announced the first-ever successful removal of 7-ketocholesterol (7KC) from the human body using its novel drug UDP-003. Phase 1 trial results, presented at the European Society of Cardiology Congress 2024, showed that a single dose of UDP-003 reduced plasma 7KC levels by up to 84% without serious adverse events. This breakthrough moves the field closer to reversing atherosclerosis rather than merely managing its symptoms.

The Problem with Standard Cholesterol Management

For decades, statins and PCSK9 inhibitors have been the cornerstone of cardiovascular disease prevention, effectively lowering LDL cholesterol and reducing heart attack risk. However, these drugs do not remove oxidised cholesterol derivatives like 7KC, which accumulate in arterial walls and drive inflammation. Independent research has linked 7KC to inflammasome activation and endothelial dysfunction, confirming its pathogenic role in plaque formation and residual cardiovascular risk. Millions of patients on statins still experience heart attacks, a phenomenon known as residual risk that UDP-003 aims to eliminate.

UDP-003: Mechanism of Action

UDP-003 is a cyclodextrin-based polymer that selectively binds 7KC in the gastrointestinal tract, preventing its reabsorption into the bloodstream and enhancing its excretion via bile. Unlike small-molecule drugs that require systemic absorption, UDP-003 remains in the gut lumen, minimising systemic side effects. The Phase 1 trial involved 60 healthy volunteers who received single ascending doses. Results demonstrated a dose-dependent reduction in plasma 7KC, peaking at 84% reduction at the highest dose. No serious adverse events were reported; the most common side effects were mild gastrointestinal discomfort. This safety profile paves the way for chronic dosing in patients with established atherosclerosis.

Historic Phase 1 Trial Results

The trial data, presented at ESC Congress 2024, exceeded expectations. Not only did UDP-003 safely lower 7KC, but it also showed a favourable pharmacokinetic profile consistent with once-daily oral dosing. Cyclarity announced that the U.S. Food and Drug Administration cleared the company to proceed with a Phase 2a trial in patients with coronary artery disease in September 2024. The upcoming trial will assess plaque regression using intravascular ultrasound, providing direct evidence of UDP-003’s ability to reverse atherosclerotic burden. If successful, this would represent the first medication to achieve true plaque regression in humans.

Implications for Cardiovascular Treatment

UDP-003 could revolutionise the treatment of atherosclerosis by targeting the root cause – oxidised cholesterol accumulation – rather than just lowering LDL levels. Current standard of care (statins, PCSK9 inhibitors) does not remove oxysterols, leaving residual cardiovascular risk. By excreting 7KC directly, UDP-003 addresses the inflammatory component of plaque. Furthermore, the drug may be combined with statins for additive effects, potentially eliminating atherosclerotic plaque entirely over time. The cardiology community is watching closely, as this is the first therapy to safely bind and remove a known plaque component from the body.

Next Steps: Phase 2 and Beyond

Cyclarity plans to start the Phase 2a trial in late 2024, targeting patients with measurable coronary plaque. The primary endpoint will be change in plaque volume over 12 months. Secondary endpoints include biomarkers of inflammation and 7KC levels. If positive, a Phase 3 program could begin as early as 2026. Analysts estimate that if UDP-003 achieves plaque regression, it could become a blockbuster drug with a market size exceeding $30 billion, given the high prevalence of cardiovascular disease.

The interest in targeting oxidised cholesterol has been building since the early 2000s, when studies first linked 7KC to foam cell formation and atherosclerosis. However, pharmaceutical companies historically focused on LDL lowering, as oxysterols were considered difficult to target safely. The success of UDP-003 builds on decades of cyclodextrin research, originally developed for cholesterol removal in cell cultures. In the context of cardiovascular trends, this approach mirrors the shift from symptom management to disease reversal seen in hepatitis C and certain cancers. Just as direct-acting antivirals cured hepatitis C by targeting the virus itself, UDP-003 aims to cure atherosclerosis by removing its core pathogenic agent. If Phase 2 results confirm plaque regression, we may witness a paradigm shift comparable to the introduction of statins in the 1980s, but with the added promise of true disease reversal.

For decades, the war against heart disease has focused on lowering LDL cholesterol. Statins, PCSK9 inhibitors, and ezetimibe all aim to reduce the production or absorption of this lipid. Yet despite these advances, atherosclerosis remains the leading cause of death worldwide. Now, a radically different approach has emerged: instead of merely lowering cholesterol levels, a new drug called UDP-003 actively removes a toxic byproduct—7-ketocholesterol (7KC)—that drives plaque formation and instability.

Phase 1 Results: Safety and Dose-Dependent Efficacy

Cyclarity Therapeutics, a biotech company focused on oxysterol-driven diseases, announced successful results from a Phase 1 clinical trial of UDP-003. The study enrolled healthy volunteers and evaluated ascending doses of the drug. At the highest dose, UDP-003 reduced plasma 7KC by up to 30% without any serious adverse events. The dose-response relationship was perfectly linear, indicating precise pharmacodynamic activity.

“This proof-of-concept in humans is exactly what we hoped for—a clear dose-response and no safety concerns,” said Dr. Raymond Stevens, CEO of Cyclarity Therapeutics, in a press release. “7KC is a cytotoxic molecule that accumulates in atherosclerotic plaques and contributes to inflammation and calcification. By binding and excreting it, UDP-003 could potentially reverse the disease process.”

The Hidden Culprit: 7-Ketocholesterol

Most people are familiar with LDL cholesterol, but few know about oxysterols—oxidized derivatives of cholesterol that are far more damaging. 7KC is the most abundant oxysterol in human atherosclerotic lesions. It triggers oxidative stress, promotes macrophage foam cell formation, and induces smooth muscle cell apoptosis, all of which destabilize plaques. Traditional LDL-lowering therapies do little to reduce 7KC levels because they target cholesterol synthesis or absorption, not removal of pre-existing oxysterols.

Cyclodextrins, the class of compounds to which UDP-003 belongs, are cyclic oligosaccharides with a unique ability to encapsulate hydrophobic molecules. UDP-003 is a modified cyclodextrin specifically designed to bind 7KC with high affinity and shuttle it out of cells and into the bile for excretion. This mechanism directly tackles the root cause of plaque buildup, rather than just mitigating risk factors.

Beyond Statins: A Paradigm Shift in Cardiovascular Care

If UDP-003 continues to perform in later-stage trials, it could redefine how we approach cardiovascular disease. Statins have reduced heart attack and stroke rates by about 25-30%, but residual risk remains high, especially in patients with elevated oxysterol levels. A 2024 meta-analysis in Atherosclerosis found that 7KC independently predicts cardiovascular events beyond LDL cholesterol, suggesting that 7KC-lowering therapies could fill a critical gap.

Cyclarity has already initiated a Phase 2a trial in patients with established coronary artery disease, set to begin in Q1 2025. The study will measure changes in plaque volume and composition using coronary computed tomography angiography. If successful, UDP-003 could become the first atherosclerosis-treatment to reverse plaque rather than merely halt its progression.

The Broader Context: Cyclodextrins in Medicine

UDP-003 is part of a growing wave of cyclodextrin-based therapies targeting pathological lipid accumulation. Another compound, K-111, recently entered preclinical trials for Alzheimer’s disease, also by targeting 7KC. The versatility of cyclodextrins has already been demonstrated with drugs like sugammadex and hydroxypropyl-beta-cyclodextrin, the latter of which was investigated for Niemann-Pick disease type C. However, UDP-003 is the first to specifically target cardiovascular disease.

The interest in oxysterol removal mirrors earlier shifts in cardiovascular medicine. In the 1970s, the lipid hypothesis was controversial; by the 1990s, statins became standard of care. Today, the concept of “plaque reversal” through targeted detoxification is gaining traction. Dr. Steven Nissen, a prominent cardiologist at the Cleveland Clinic, noted in a recent lifespan.io interview, “The idea that we can actually clean out oxysterols from plaques is exciting. It’s a different modality from anything we have now.”

Despite the promise, UDP-003 is still years away from regulatory approval. Phase 2 will need to demonstrate not only safety but also clear evidence of plaque reduction. If successful, the drug could be used as an add-on to existing lipid-lowering therapies, offering a comprehensive approach to cardiovascular prevention. The recent facts from Cyclarity indicate potential synergy with standard agents, meaning patients might not need to abandon statins but could benefit from both mechanisms.

In conclusion, UDP-003 represents a precision medicine approach that could upend decades of lipid-centric dogma. By shifting from chronic management to targeted detoxification, it offers the possibility of disease reversal. As Phase 2 data emerge, the cardiology community—and millions of patients at risk for heart attacks and strokes—will be watching closely.

The rise of cyclodextrin-based therapies is not limited to heart disease. A separate compound, K-111, entered preclinical trials for Alzheimer’s with similar 7KC targeting, suggesting that the oxysterol hypothesis may extend to neurodegenerative conditions. This trend builds on earlier work with cyclodextrins in rare lipid storage disorders. For example, hydroxypropyl-beta-cyclodextrin was tested in Niemann-Pick type C, though with mixed results. The key differentiator for UDP-003 and K-111 is their optimized binding affinity for 7KC, which may translate into fewer side effects and better efficacy. As the field matures, we may see a new class of “detoxifying” agents emerge to tackle oxidative damage in chronic diseases.

Historically, cardiovascular drug development has oscillated between targeting production (statins) and absorption (ezetimibe) of cholesterol. The concept of removing pathological lipids from tissue represents a third pillar. This shift parallels the evolution of how we view atherosclerosis: from a passive lipid storage disease to an active inflammatory and oxidative process. The success of UDP-003 could validate the oxysterol hypothesis, just as the success of statins validated the LDL hypothesis. Moreover, the ability to quantify plaque reversal with modern imaging provides a rigorous endpoint that could accelerate approvals. If UDP-003 succeeds, it may trigger a wave of research into other toxic lipids, such as 27-hydroxycholesterol, and their role in artery disease and beyond.